Singapore Medical Group Ltd
SGX:5OT

Watchlist Manager
Singapore Medical Group Ltd Logo
Singapore Medical Group Ltd
SGX:5OT
Watchlist
Price: 0.395 SGD Market Closed
Market Cap: S$190.7m

Cash Flow Statement

Cash Flow Statement
Singapore Medical Group Ltd

Rotate your device to view
Cash Flow Statement
Currency: SGD
Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Jun-2020 Dec-2020 Jun-2021 Dec-2021 Jun-2022
Operating Cash Flow
Net Income
9
12
13
14
14
14
14
15
16
12
11
15
18
17
Depreciation & Amortization
3
3
4
4
4
5
6
8
9
9
9
9
9
10
Other Non-Cash Items
1
1
1
0
1
1
1
2
2
2
2
1
(2)
(2)
Cash Taxes Paid
0
0
1
1
1
1
1
1
2
1
1
3
2
2
Cash Interest Paid
0
1
1
1
1
1
1
1
1
1
1
1
0
0
Change in Working Capital
(0)
(2)
(1)
(2)
(2)
(2)
(1)
0
(1)
1
(1)
(5)
(1)
1
Cash from Operating Activities
13
N/A
14
+7%
16
+17%
16
-1%
17
+10%
19
+8%
21
+12%
24
+15%
26
+8%
25
-4%
21
-16%
21
+0%
24
+17%
25
+2%
Investing Cash Flow
Capital Expenditures
(5)
(6)
(7)
(6)
(3)
(3)
(2)
(2)
(2)
(1)
(2)
(4)
(4)
(2)
Other Items
(17)
(23)
(24)
(24)
(25)
(20)
(20)
(18)
(17)
(5)
(2)
(1)
(5)
(6)
Cash from Investing Activities
(22)
N/A
(29)
-31%
(31)
-5%
(29)
+4%
(29)
+2%
(23)
+20%
(22)
+2%
(20)
+9%
(19)
+8%
(6)
+69%
(3)
+43%
(6)
-67%
(10)
-72%
(8)
+17%
Financing Cash Flow
Net Issuance of Common Stock
16
1
1
7
7
7
8
1
1
(0)
(0)
0
1
0
Net Issuance of Debt
8
4
4
4
3
(2)
6
3
(0)
(24)
(17)
(7)
(11)
(9)
Cash Paid for Dividends
0
0
0
0
0
0
0
0
0
0
(2)
(4)
(2)
(4)
Other
(1)
(0)
(0)
(0)
(1)
0
(1)
(1)
(0)
0
(0)
(0)
(1)
(1)
Cash from Financing Activities
23
N/A
4
-81%
4
+5%
11
+154%
10
-12%
4
-55%
13
+185%
3
-79%
(0)
N/A
(25)
-40 862%
(19)
+22%
(11)
+43%
(14)
-27%
(14)
-4%
Change in Cash
Net Change in Cash
14
N/A
(11)
N/A
(10)
+10%
(2)
+80%
(1)
+35%
0
N/A
11
+2 449%
6
-44%
7
+14%
(5)
N/A
(2)
+69%
4
N/A
1
-77%
3
+154%
Free Cash Flow
Free Cash Flow
8
N/A
8
-3%
9
+21%
10
+12%
14
+37%
15
+11%
19
+22%
22
+17%
24
+8%
24
-1%
19
-19%
17
-14%
20
+22%
23
+13%
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett